Roivant Social Ventures

?? EXTENDED DEADLINE ?? — There is still time to apply for our spring fellowship. Are you a student or young professional interested in biotech and health policy? Apply by February 15. Join future biotech leaders in a 10-week program that unites lessons on health economics, investing, and insurance design with lectures from industry leaders. Fellows will have the opportunity to connect with like-minded peers and collaborate on impactful projects. The NPLB Fellowship is fully virtual, and you can participate from anywhere in the world. See our application below and please start today to make sure you are able to complete the necessary prerequisites before February 15! https://lnkd.in/g2Q9vr2A

Time is running out to apply for Springboard Enterprises' 2025 Women’s Health Accelerator Program! ? If you’re a female founder solving problems in women’s health and are ready for the next big leap, this is your moment. What makes Springboard unique? ? Unmatched Expertise – 25 years of breaking down barriers for female founders ? Growth at Key Inflection Points – Navigate scaling, fundraising & new opportunities ? Tailored Support – Personalized advisor matches based on your industry & trajectory ? Investor Access – A deep network of women’s health investors, with direct advisor matching ? Lifelong Community – Springboard is more than an accelerator—it’s a network for life ?? “The Springboard Enterprises Women’s Health Cohort combines resources, knowledge, and community to elevate women's health founders and their companies.” – Kate Liebelt, Executive in Residence & Chief of Staff, Business Strategy and Operations, Medical Affairs at Genentech ?? Don’t miss your chance to accelerate your company’s success! Apply now before it’s too late: https://shorturl.at/zbIpC #SpringboardAccelerator #WomensHealth #FemaleFounders #OneWeekLeft

This week Roivant Social Ventures had the pleasure of attending the 2025 Biotechnology Innovation Organization (BIO) CEO & Investor Conference! This annual two-day conference provides a forum where institutional investors, industry analysts, and senior executives have the opportunity to shape the future investment landscape of the biotechnology industry to result in better patient outcomes. Programming this morning kicked off with our President and CEO Lindsay Androski, CFA speaking on the "Policy Outlook: Navigating a New Congress and Executive Branch" panel. With the election of a new Congress, President, and agency leadership, there are questions about the trajectory of policies and guidelines and what will change for the biotech industry. As new priorities emerge, understanding the landscape and leadership is top of mind. This session offered an inside the Beltway perspective on the year ahead in Washington and allowed discussion with company leaders, policy experts, and investors to highlight priorities moving forward. The talented group of expert panelists also featured: - Moderator Anna Abram, Senior Advisor, Health Care Policy and Legislation at?Akin Gump Strauss Hauer & Feld LLP - Remy L. Brim , Ph.D., Principal, Health Care Practice Head,?BGR Group Government Affairs, LLC - Peter Norman, Senior Vice President, Policy and Government Relations,?Alkermes - Michele Oshman, Senior Vice President, External Affairs and Head, Patient Advocacy Center of Excellence,?Biotechnology Innovation Organization United States Thank you to BIO for hosting this event filled with impactful partnering meetings, thought-provoking sessions, and valuable connections. #BIOCEO25 #BIOCEOInvestor #biopharma #drugdevelopment #policy #policyoutlook #pharma #medicine #medicines #healthcare #healthcareaccess

Day 2 at the BIO CEO & Investor Conference Conference is off to a great start! Lots of great discussions, including a panel on navigating the new Congress and Executive Branch. Hearing some great insights from Lindsay Androski, CFA (Roivant Social Ventures), Remy L. Brim , Ph.D. (BGR GOVERNMENT AFFAIRS, LLC), Peter Norman (Alkermes), and Michele Oshman (Biotechnology Innovation Organization) on the regulatory landscape and its impact on biopharma innovation was invaluable. With Axio BioPharma focused on accelerating drug development, staying ahead of these shifts is key. Looking forward to more great conversations throughout the day! #BIOCEOInvestor #Biopharma #DrugDevelopment #Policy #AxioBioPharma

Congratulations to Diana Locoteta on being chosen for Roivant's two-year PharmD Post-Doctoral Fellowship in Research and Development! In 2023 Diana was part of Roivant Social Ventures' Access to Medicines Internship program, which provides real-world drug development experience to talented PharmD students. We designed this internship program to increase industry exposure, with the hopes of creating more direct pathways for PharmD students to pursue industry work that leverages their important skillsets to positively impact the world of drug development. We are thrilled to see that through her hard work and dedication, Diana has directly accomplished these goals! Diana also completed RSV's "Making Medicines" course at the UNC Eshelman School of Pharmacy, the top ranked School of Pharmacy in the United States. This innovative course was designed to introduce PharmD students to the new drug approval process and key issues in drug discovery, pre-clinical testing, clinical trials, FDA approval, and global access to medicines. The course is taught by Lindsay Androski, CFA, RSV Founder & CEO, and Scott Singleton, Associate Professor at the UNC Eshelman School of Pharmacy. Read more about Diana's background and internship experience with Psivant Therapeutics here: https://lnkd.in/gXfQcrXV #healthcare #internship #internships #impact #medical #pharma #therapeutics #therapeutic #medicine #medicines #socialimpact #medical #medicaldevices #tech #technology #techforgood #access #accessibility #healthcarenews #healthcareinnovation #drugdiscovery #drugdevelopment #biopharma #pharmaceuticalindustry

We are excited to share that Lindsay Androski, CFA, Roivant Social Ventures President and CEO, has been appointed to the 2025 BIO CEO & Investor Conference Advisory Committee! The annual Biotechnology Innovation Organization (BIO) CEO & Investor Conference provides a forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry to result in better patient outcomes. The Advisory Committee is an esteemed group of industry thought leaders assembled by BIO to shape the conference program. View the full 2025 Advisory Committee here: https://lnkd.in/g2cpbBrd Learn more about the conference here: https://bcic.bio.org/ #BIOCEO25

CARER Group Named Finalist for Fierce Pharma's Innovative DEI Training and Education Award The?Fierce Pharma DEI Awards?celebrate and recognize outstanding achievements in Diversity, Equity, and Inclusion (DEI) within the healthcare industry. This program honors organizations, initiatives, and individuals who are making significant strides in creating a more equitable and inclusive healthcare environment. Submissions were evaluated on innovation and impact, measurable outcomes, sustainability and scalability, and ethical considerations.? ? The?Catalyzing?Access to?Research and?Equity?Representation (CARER Group) Group?is made up of a group of Biotech professionals who have come together to draw awareness to the inequities that currently exist in the healthcare industry. They have developed the?Clinical Trial Diversity (CTD) Score Card,?a reporting and scoring system designed to evaluate diversity in the registrational clinical trials for novel drugs and biological products approved by US Food & Drug Administration (FDA).?Since its launch in 2022, the CARER Group has scored every FDA approved drug. Roivant?Social?Ventures?was a founding member of the CARER Group. View Clinical Trial Diversity Scorecards: https://lnkd.in/gnXGcWYH Visit CARER's Website: https://carergroup.org/ Fierce Pharma DEI Awards Page: https://lnkd.in/ebSaa6-2 ?

Last week Mackenzie Greene and Magdalene Mallory, Roivant Social Ventures 2024 Global Access Fellows, presented on their recent work in Kigali, Rwanda at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition! Within their roles as Global Access Fellows Greene and Mallory volunteered with Goodlife Access to: - Conduct community healthcare clinic days that are creating access to otherwise unavailable blood pressure and blood glucose screenings for hundreds of community members in Kigali. - Create patient materials for post-screening healthcare education that provide next steps for building better health. - Standardize screening techniques for providers to promote sterile practice, patient privacy, and continuity of care. - Assist in the opening of new pharmacies. - Create non-communicable disease screening/consultation rooms, including their scheduling, building, budgeting, staffing requirements, and educational marketing materials for community members. ASHP is the largest association of pharmacy professionals in the United States, representing 60,000 pharmacists, student pharmacists, and pharmacy technicians in all patient care settings, including hospitals, ambulatory clinics, and health-system community pharmacies. #drugdevelopment #pharma #medicine #medicines #healthcare #healthcareaccess #biopharma #globalimpact?UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill

Reminder: December 15th deadline Approaching for Call for Grant Proposals on Evidence-Based Biopharma Policy The Information Technology and Innovation Foundation (ITIF), will offer three grants of $50,000 for new research that addresses the lack of sufficient?credible and recent evidence to inform?public policy changes impacting biopharmaceutical drug development. Funded research will support a better understanding of how the expectation of a financial return from investment in clinical biopharmaceutical development affects the level of investment in all stages of clinical development and for different types of potential drugs, such as for rare diseases, oncology, or vaccines. Click here to learn more about this funding opportunity, including preferred topics, application requirements, and submission instructions: https://lnkd.in/gj54UxDd

Did you know that until the 1990s women were actively excluded from participating in clinical trials and most medical research? This longtime bias put the health of women at risk and created a huge gap in knowledge about women’s health?and the role that differences between women and men play in health and disease. Thanks to advocacy by The Society for Women's Health Research (SWHR) and other groups, Congress passed The National Institutes of Health Revitalization Act of 1993, mandating the inclusion of women and underrepresented groups in NIH-funded clinical trials. In the same year, the FDA changed its policies to require the inclusion of women in efficacy studies and in the analysis of data on sex differences. The SWHR is a national thought leader dedicated to advancing women’s health and promoting research on sex differences to optimize women’s health. This organization plays a critical role in identifying clinical and research gaps; raising awareness of diseases, conditions, and life stages that differently, disproportionately, or exclusively affect women; and promoting policies that could positively shape health outcomes for women. Over its more than 30-year history, SWHR has been advancing women’s health through its core functions of science, policy, and education. In addition to housing a large database of programmatic and policy resources, SWHR also hosts the Women’s Health Perspectives series, which includes firsthand accounts of individuals’ personal health care and/or caregiving experiences. Recent featured stories include topics such as Endometriosis, Menopause, Breast Cancer, PCOS, and Uterine Fibroids. Access the Women’s Health Perspectives series and learn how you can share your story here: https://lnkd.in/gikKCg4C